The study also found an improvement in the placebo group: https://www.businesswire.com/news/home/20210323005208/en/Fre...

Interesting approach, I'd love to see it work. But given the mixed results plus the class action lawsuits that still seem unsettled (at least I didn't find any news), this doesn't really seem investable to me. Biotech startups are risky enough even without such problems.